Previous studies on nonsteroidal antiinflammatory drugs (NSAIDs) and breast cancer have produced mixed results. Incident invasive cases of breast cancer from the Multiethnic Cohort (African Americans, Caucasians, Japanese Americans, Latinas, and Native Hawaiians from Hawaii and California) were identified from 1993 to 2002. Data on aspirin, acetaminophen, and other NSAID (ibuprofen, naproxen, indomethacin) use were based on a self-administered questionnaire at baseline (1993)(1994)(1995)(1996). Multivariate Cox proportional hazards models provided estimates of hazard rate ratios and 95% confidence intervals. The authors observed no associations between breast cancer risk and duration of aspirin use for current or past users (hazard rate ratio ¼ 1.05, 95% confidence interval: 0.88, 1.25 and hazard rate ratio ¼ 1.04, 95% confidence interval: 0.84, 1.27 for 6 years of use, respectively) compared with nonusers. However, duration of current other NSAID use was protective (hazard rate ratio ¼ 0.70, 95% confidence interval: 0.51, 0.95 for 6 years of use; p trend ¼ 0.01) against the risk of breast cancer, while past use was not (hazard rate ratio ¼ 0.90, 95% confidence interval: 0.62, 1.30 for 6 years of use). Analyses by ethnicity and hormone receptor status showed that the protective effect of current other NSAID use was limited to Caucasians and African Americans and to women with at least one positive hormone receptor. This study found duration of current other NSAID use to be protective against breast cancer risk.
Studies of breast tumors from humans and animals have suggested that cyclooxygenase (COX)-2 expression is associated with breast cancer development (1) . COX-2 is an enzyme involved in the biosynthesis of prostaglandins. Increased COX-2 levels are associated with increased angiogenesis and estrogen synthesis and with reduced apoptosis (2) . COX-2 up-regulation leads to overexpression of prostaglandin E 2 , which is thought to promote local estrogen biosynthesis via aromatase activity (1) and therefore increase risk of breast carcinogenesis. Nonsteroidal antiinflammatory drugs (NSAIDs) may reverse the expression of prostaglandin E 2 (3), thereby reducing the local production of estrogens. A 2001 meta-analysis of any NSAID use and risk of breast cancer reported an odds ratio of 0.80 (95 percent confidence interval (CI): 0.73, 0.87) (4) , and a recent pooled analysis of aspirin use and breast cancer reported a risk ratio of 0.90 (95 percent CI: 0.87, 0.94) (5) . However, two recent, large cohort studies observed no protective effect of NSAID or aspirin use (6, 7) . This analysis examines the association of duration of aspirin, other NSAIDs, and total NSAID use with breast cancer risk among female members of the Multiethnic Cohort (8) .
MATERIALS AND METHODS

Study population
Details of the Multiethnic Cohort have been described previously (8) . In brief, data were collected between 1993 and 1996 by using a 26-page, self-administered, mail questionnaire sent to residents of Hawaii and California, mainly Los Angeles County. The institutional review boards at both locations approved the study. Subjects were identified through drivers' license records in both locations; in addition, voter registration records were used in Hawaii and Health Care Financing Administration files in California. African Americans, Caucasians, Japanese Americans, Latinas, and Native Hawaiians were the primary targets for recruitment, but a small number of persons of other ethnicities were also enrolled in the study. Participation in the cohort was limited to people aged 45-75 years in 1993, except for Native Hawaiians, who were recruited at age 42 years or older. The Multiethnic Cohort data set consists of 215,251 people, of whom 118,869 are women. The following women were excluded from this analysis: 1) 8,051 who do not belong to one of the five major ethnic groups; 2) 4,611 whose dietary records were invalid; 3) 6,654 who had a prior history of breast, uterine, or ovarian cancer based on questionnaire or cancer registry data because their cancer treatment may affect their risk of breast cancer; and 4) 633 diagnosed with in situ breast cancer during follow-up. Therefore, data on 98,920 women were available for this analysis.
Data collection
The questionnaire included demographic information, body weight and height, medication history, and dietary history (8) . The following question was asked to assess pain medication use: ''Have you ever taken any of the following medications at least two times per week (for 1 month or longer)?'' The question was posed once for each of three categories of pain medication-aspirin, other NSAIDs (ibuprofen, naproxen, indomethacin, or other), and acetaminophen-and examples of brand names were provided. Cohort participants responded by circling ''no,'' ''yes, but not at this time,'' or ''yes, currently.'' If participants answered ''yes,'' they were asked to mark the length of medication use as 1 year or less, 2-3 years, 4-5 years, 6-10 years, or 11 years or more.
Case identification and follow-up
Follow-up time started at the date of entry into the cohort, defined as questionnaire completion or the date of the 45th birthday for the few Multiethnic Cohort members younger than age 45 years at baseline. Follow-up ended at the earliest of the following dates: 1) breast cancer diagnosis, 2) ovarian or uterine cancer diagnosis, 3) death, or 4) last date of follow-up. Breast cancer was the event of interest. Incident cases of cancer were identified through linkages with the Los Angeles County Cancer Surveillance Program, the State of California Cancer Registry, and the Hawaii Tumor Registry, all members of the Surveillance, Epidemiology, and End Results Program supported by the National Cancer Institute. Information on deaths was obtained from the vital statistics offices in both states and the National Death Index. Case ascertainment was complete through December 31, 2002. All invasive breast cancer cases were identified for the analysis.
Statistical analysis
We created four categories for use of aspirin, acetaminophen, and other NSAIDs: no use, up to 1 year, 2-5 years, and 6 years or more. We also created a total NSAID use variable (no use, up to 1 year, 2-5 years, 6-10 years, and 11 years or more), which combined years of use for aspirin and other NSAIDs, but not acetaminophen. The total NSAID variable summed total years of aspirin use and total years of other NSAID use; if duration information on one variable was missing, then total years of NSAID use was also assigned as missing. We had individuals who reported using pain medications but did not indicate the number of years of use, which we then treated as missing (3.0 percent for aspirin, 4.6 percent for other NSAIDs, and 5.0 percent for acetaminophen; table 1). Therefore, the total amount of missing information on pain medication use was 7.9 percent for aspirin, 10.8 percent for other NSAIDs, and 11.2 percent for acetaminophen.
We applied multivariate Cox proportional hazards regression models with age as the time metric to estimate hazard rate ratios and 95 percent confidence intervals while adjusting for covariates (9) . The analysis was stratified by followup period (2 years, >2-5 years, 5 years) in an attempt to account for any change in associations over time. The Cox proportional hazards assumption was tested by examining Kaplan-Meier survival curves and by assessing Schoenfeld residuals. All analyses were completed by using SAS version 9.1 software (10). All reported p values are two sided.
We used two models throughout the analyses: one model with the aspirin-, other NSAID-, and acetaminophen-use variables and a second model with total NSAID-and acetaminophen-use variables. All pain medications were considered in the models to adjust for pain-medicationtaking behavior. Women who had never used any of the pain medications were the reference group for all models. We analyzed the association of each pain medication (aspirin, acetaminophen, other NSAIDs, and total NSAIDs) with breast cancer in two ways. First, the hazard rate ratio for each pain medication was estimated by adjusting for age at cohort entry and ethnicity (African American, Caucasian, Japanese American, Latina, and Native Hawaiian) only. Next, we added the baseline values for family history of breast cancer (none, mother/sister/daughter diagnosed with breast cancer), mammography screening history (never, more than 2 years ago, within 2 years), education (up to 12 years, more than 12 years), body mass index (<25, 25-<30, 30 kg/m 2 ), alcohol intake (1 drink per day, >1-<2 drinks per day, 2 drinks per day), age at menarche (12, 13-14, 15 years), age at first full-term pregnancy (nulliparous, 20, 21-<31, 31 years), number of children for parous women (1, 2-3, 4), age at and type of menopause (natural: age <45, 45-<50, 50-<55, 55 years; oophorectomy: age <45, 45-<50, 50 years; hysterectomy: age <45, 45-<50, 50 years), and use of hormone replacement therapy (none, estrogen only, estrogen/progestin). Variables for trend tests were created by using the median value for each duration of use category (1 year, 2-5 years, etc.) for each pain medication. Tests for interaction were performed by using the Wald test, jointly comparing all interaction terms of duration of pain medication use and an indicator variable for current/past use against null values of zero (11).
After we excluded women for whom values for model covariates were missing, 78,797 women remained.
We also performed separate analyses by ethnicity, body mass index (<25 and 25 kg/m 2 ), use of hormone replacement therapy (no use, any use), and estrogen and progesterone receptor status (at least one positive receptor (estrogen and/or progesterone), no positive receptors).
RESULTS
For each of the three pain medications, nearly 60 percent of all study subjects stated that they had never used the A test of interaction between duration and an indicator variable of current/past use of other NSAIDs suggested a possible interaction (p interaction ¼ 0.07), signifying that total duration of current and past use should not be combined.
Total NSAID use-current or past-was not associated with breast cancer (11 years of use: hazard rate ratio ¼ 0.99, 95 percent CI: 0.82, 1.18 for current use and hazard rate ratio ¼ 1.01, 95 percent CI: 0.82, 1.25 for past use). Acetaminophen, in accordance with its lack of COX-2 inhibitory properties, was not associated with breast cancer risk (6 years of use: hazard rate ratio ¼ 0.87, 95 percent CI: 0.71, 1.06 for current use and hazard rate ratio ¼ 1.05, 95 percent CI: 0.83, 1.33 for past use). We also examined the association of each pain medication with in situ breast cancer and found no associations (results not shown).
We observed the protective association of current duration of other NSAID use with breast cancer for AfricanAmerican and Caucasian women only (table 3, p trend ¼ 0.02 for both ethnic groups). African-American women's risk decreased by 60 percent if they were current users of other NSAIDs for 6 or more years (95 percent CI: 0.17, 0.91), whereas Caucasian women had a 40 percent decrease in risk (95 percent CI: 0.36, 1.02). However, past other NSAID use did not decrease risk of breast cancer for any of the ethnic groups, although there was a suggestion of a trend with duration for Caucasian women (p trend ¼ 0.08). For Japanese, Latina, and Native-Hawaiian women, we found no association with current or past other NSAID use. Aspirin use was not associated with breast cancer for any of the ethnic groups, nor was total NSAID use.
Information on estrogen receptor and progesterone receptor status of tumors was available through our registries for 80 percent of all cases. Cases for whom information on estrogen receptor and progesterone receptor status was or was not available did not differ in their distribution of current/past aspirin or other NSAID use. Analyses by subgroups of women with breast cancer who had at least one positive estrogen receptor and/or progesterone receptor compared with women with both receptors negative showed differences in the strength of association by duration of current (p trend
Stratification by weight status as measured by body mass index did not indicate any differences in breast cancer risk estimates between overweight (25 kg/m 2 ) and normalweight (<25 kg/m 2 ) women (results not shown). Use of hormone replacement therapy also did not change the association between current or past pain medication use and risk of breast cancer (results not shown).
DISCUSSION
We observed no association between aspirin use or total NSAID use and breast cancer risk among the female members of the Multiethnic Cohort study, but we did observe a protective effect of other NSAID use among current users. Longer duration of current other NSAID use was associated with a greater protective effect against breast cancer (p trend ¼ 0.01), and use for 6 or more years decreased risk by 30 percent. Past use of other NSAIDs was not associated with risk of breast cancer, suggesting a possible interaction between timing (current/past) of other NSAID use and duration (p interaction ¼ 0.07). After we performed analyses by ethnicity and by subgroups of hormone receptor status, the protective effect for the longest duration of current other NSAID use was limited to Caucasian and African-American women and to women with at least one positive hormone receptor.
Our findings agree with results from some cohort studies of NSAID use and breast cancer (12, 13) but not with others (6, 7, 14) . The Women's Health Initiative and a Canadian cohort study of NSAIDs and aspirin found aspirin and other NSAIDs to be protective against breast cancer (12, 13) . On the other hand, the Iowa Women's Health study (14) observed that daily aspirin use, but not use of the other NSAIDs, was protective against breast cancer, and the California Teacher's study and the American Cancer Society Cohort found neither aspirin nor ibuprofen to have a protective effect (6, 7). The California Teacher's study actually observed a higher risk of breast cancer with daily, regular ibuprofen use (risk ratio ¼ 1.24, 95 percent CI: 1.07, 1.44). The lack of an association between aspirin use and breast cancer in our study may be a result of women taking primarily low-dose aspirin for heart disease prevention. As shown by a randomized trial and an observational study, low-dose aspirin does not appear to lower invasive breast cancer risk (13, 15) . Data from our study suggested a heterogeneity of effect by timing for other NSAID use, but two other studies that analyzed timing of NSAID use (7, 16) did not find differences such as ours. However, they did not analyze duration of current use and duration of past use separately. One study looked at current use versus past use for less than * Nonusers were the reference group. y Adjusted for age, body mass index, family history of breast cancer, education, mammography screening, alcohol intake, age at menarche, age at first livebirth, number of children, menopausal status, age at menopause, and hormone replacement therapy. Models were adjusted for all pain medication use.
5 years and past use for 5 or more years (16) , while the other study compared past or less-than-regular use with current, regular use for less than 5 years and use for 5 or more years (7). The differences we observed across ethnic groups, especially among current users of other NSAIDs, could be due to biology, such as COX-2 polymorphisms, or they could reflect differences in patterns of and reasons for medication use. They could also be the result of residual confounding or unmeasured confounding. More research is required to clarify the role of timing of NSAID use on breast carcinogenesis as well as potential differences in risk across ethnic groups.
Similar to our study, a few others have found different patterns of risk by estrogen or progesterone receptor status (6, 16) , but the findings have been inconsistent. Although our study found a protective association between breast cancer with at least one positive hormone receptor and duration of current other NSAID use but not duration of current aspirin use, the Long Island Breast Cancer Study Project found current and former aspirin use to have similar protective risk estimates for breast cancer cases with at least one positive hormone receptor (odds ratio ¼ 0.74, 95 percent CI: 0.57, 0.96 and odds ratio ¼ 0.79, 95 percent CI: 0.55, 1.13, respectively) (16) . The California Teacher's Cohort found 5 or more years of daily aspirin use to suggest protection against breast cancer among women with estrogen-or progesterone-positive tumors (risk ratio ¼ 0.80, 95 percent CI: 0.62, 1.03), while a similar duration and frequency of ibuprofen use increased risk of breast cancer (risk ratio ¼ 1.50, 95 percent CI: 1.11, 2.03) (6) . Further adding to the inconsistencies, the American Cancer Society Cohort and a 2005 case-control study found no difference in the association between NSAID use and breast cancer risk by hormone receptor status (7, 17) . Thus, more research is needed before any conclusions can be made about the role of NSAIDs in the incidence of hormone-receptor-positive tumors.
Our study found no differences in risk for overweight (25 kg/m 2 ) compared with normal-weight (<25 kg/m 2 ) women. Results from three previous studies support our findings. A population-based case-control study and the American Cancer Society Cohort found no difference with aspirin and/or NSAID use across strata of body mass index (7, 18) , and, whereas the Women's Health Initiative study found a 29 percent reduction in risk for women with a body mass index of 27 kg/m 2 who used any NSAID for 5 or more years, a test for heterogeneity of effect was not statistically significant (12) . Similarly, our study supports results from previous research showing that use of hormone replacement therapy does not change the relation between aspirin and/or NSAID use and breast cancer (7, 12, 16) .
Menopausal status may modify the association between NSAIDs and breast cancer. A statistically significant reduction in risk was described for premenopausal but not postmenopausal women in one case-control study of NSAIDs (17) , but another case-control study of aspirin use found just the opposite (16) . The Nurses' Health Study observed a lower relative risk for aspirin users under age 50 years than for older women (0.79 and 1.06, respectively) (19) . Since the Multiethnic Cohort is mostly composed of * Adjusted for age, ethnicity, body mass index, family history of breast cancer, education, mammography screening, alcohol intake, age at menarche, age at first livebirth, number of children, menopausal status, age at menopause, and hormone replacement therapy. Models were adjusted for all pain medication use.
y Women for whom values for any of the pain medications were missing were excluded from this analysis (n ¼ 11,742).
z Nonusers were the reference group. § HR, hazard rate ratio; CI, confidence interval; NSAIDs, nonsteroidal antiinflammatory drugs.
{ Includes aspirin and other NSAIDs.
postmenopausal women, we were unable to address this question. In contrast to relatively inconsistent results of cohort studies, the majority of case-control studies that examined aspirin or NSAID use reported them to be protective against breast cancer (4, 17, 18, (20) (21) (22) (23) (24) . A recent pooled analysis of aspirin use and breast cancer produced risk ratios of 0.94 (95 percent CI: 0.90, 0.98) for 12 cohort studies and 0.80 (95 percent CI: 0.73, 0.87) for six case-control studies (5) .
The inconsistencies across studies may be due to differences in exposure classification, study design, definition of use, age at data collection and start of medication, prevalence of medication use, and choice of covariates. Casecontrol studies appear to be more likely to report protective effects of NSAIDs (aspirin and/or ibuprofen). Recall bias and selection bias may be partly responsible for this repeated observation. The variations in results may also be due to unmeasured confounders, such as frequency of contact with health care providers and higher screening rates for women who obtain regular prescriptions. Compared with that for populations in other locations, the Multiethnic Cohort screening rate is relatively high; 89.7 percent of Caucasians, 87.9 percent of African Americans, 84.5 percent of Native Hawaiians, 88.9 percent of Japanese, and 81.4 percent of Latinas reported having had a previous mammogram.
Strengths of our study are the prospective design and the large number of breast cancer cases from different ethnic groups. In addition, recall bias should be minimal because medication use was ascertained before breast cancer diagnosis. A serious limitation of this study is a lack of detailed data on the frequency of medication use, dosage, and age at initiation that may have resulted in misclassification of exposure. We could not assess whether women were concurrently using the various pain medications or whether the patterns of use were unchanged until the time of diagnosis. Therefore, we assumed that aspirin and other NSAID use was nonconcurrent when analyzing by total NSAID use and that women's reported patterns of use at baseline did not change. We did not have data on the reasons for pain medication use and thus could not assess the role of comorbidities in duration of use. Our study had limited power for analyses of current or past pain medication use across the different ethnic groups and for analysis of estrogen-receptor-/progesterone-receptor-negative tumors. Furthermore, when the cohort was established, newer NSAIDs, such as selective COX-2 inhibitors, had not entered the market yet. Therefore, we were not able to study their effects.
In summary, this investigation suggests that the relation between other NSAID use and breast cancer may vary by timing of use, although we observed no associations for aspirin or total NSAID use, regardless of timing. Long-term current use of other NSAIDs appeared to be protective against breast cancer for Caucasians and African Americans and for women with at least one positive hormone receptor. There is much debate about the possible role of COX-2 inhibitors in breast cancer chemoprevention. However, the literature is inconsistent, and the benefits of such a regimen must be weighed against the potential side effects. It would be valuable for future research on NSAIDs to include a detailed assessment of medication use including frequency, duration, dose, type, and timing in addition to information on the frequency of contact with the health care system and comorbidities. Further analyses also need to be conducted across ethnic groups to verify our results that duration of current other NSAID use is protective for only Caucasian and African-American women.
